C12Y 304/23005
Cathepsin d
Official title: Cathepsin D (3.4.23.5)
C12Y304/23005 (Cathepsin d) appears on 13 US grants and 18 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 18
- Assignees
- 15
- Inventors
- 36
- Latest grant
- 6 Aug 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 2 | 0 |
| 2016 | 1 | 3 |
| 2017 | 0 | 2 |
| 2018 | 1 | 2 |
| 2019 | 1 | 2 |
| 2020 | 3 | 0 |
| 2021 | 0 | 3 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Treatment of neuronal ceroid lipofuscinosis6 Aug 2024US 12,053,510 B2Orfoneuro Aps
- Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens22 Sep 2020US 10,780,179 B2Immunobiochem Corporation
- Method of detection of analyte active forms and determination of the ability of substances to bind into analyte active sites21 Jul 2020US 10,718,772 B2Ustav Organicke Chemie A Biochemie Akademie Ved Cr, V. V. I.
- Reduction of lipase activity in product formulations25 Feb 2020US 10,570,397 B2University of Deleware
- Treatment of synucleinopathies26 Feb 2019US 10,213,494 B2Genzyme Corporation
- Agent for activating a neuron1 Feb 2024US 2024/0033332 A1Kyoto University
- Methods and compositions for the treatment of amyloidosis27 Apr 2023US 2023/0127775 A1Ultragenyx Pharmaceutical Inc.
- Engineered cells with modified host cell protein profiles5 Aug 2021US 2021/0238628 A1
- Methods and compositions for the treatment of amyloidosis29 Jul 2021US 2021/0228694 A1Ultragenyx Pharmaceutical Inc.
- Treatment of neuronal ceroid lipofuscinosis10 Jun 2021US 2021/0169998 A1Orfoneuro Aps
Most cited
By later US patents
- Treatment of synucleinopathies18US 8,454,954 B2The Brigham and Women S Hospital, Inc. · 2013
- Treatment of synucleinopathies13US 10,213,494 B2Genzyme Corporation · 2019
- Phosphorothioate inhibitors of metastatic breast cancer13US 5,552,390 ABoard of Regents of the University of Nebraska · 1996
- Reduction of lipase activity in product formulations2US 9,932,591 B2University of Delaware · 2018
- Treatment of synucleinopathies1US 9,314,512 B2The Brigham and Women S Hospital, Inc. · 2016